
Lifecore Biomedical, Inc.: financial statements
Price
$6.39
November 20, 2026Market cap $239M
What Ploutos Investor adds for Lifecore Biomedical
Part of Ploutos Investor, €9.99 a month
- The full history: 16 fiscal years, from FY2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
- The latest annual figures the company filed are for 2025, more than a year ago. Newer ones may be late.
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Revenue
| Line | FY2023 | FY2024 | FY2025 | Average a year |
|---|---|---|---|---|
| Revenue | $103M | $128M | $129M | |
| Cost of revenue | $75M | $86M | $89M | |
| Gross profit | $28M | $42M | $40M | |
| Operating income | -$22M | -$8.8M | -$17M | |
| Net income | -$100M | $12M | -$39M | |
| Earnings per share | -$3.32 | $0.33 | -$1.27 | |
| Earnings per share, basic | -$3.32 | $0.39 | -$1.27 | |
| Margins | ||||
| Gross margin | 27.1% | 32.6% | 31.3% | |
| Operating margin | -21.1% | -6.9% | -13.4% | |
| Net margin | -96.4% | 9.4% | -30.0% | |
Financial statements
LFCR's revenue, profits and cash flows from FY2010 to FY2022, 13 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
By segment
Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.
- Lifecore
- Curation Foods
- FY2020: Lifecore $86M, Curation Foods $74M
| Segment | FY2020 | Share FY2020 |
|---|---|---|
| Lifecore | $86M | 54% |
| Curation Foods | $74M | 46% |
By segment
LFCR's revenue by segment from FY2014 to FY2019, 6 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Left out: FY2021, FY2022. In those filings two breakdowns were tagged at once (product lines beside regions), so the lines add up to well over the company's revenue.
From the XBRL of 13 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
When the debt falls due
Dec 31, 2025Due within 2 years
$1.9M
Total falling due
$196M
Total in the ladder $196M, from the annual report dated December 31, 2025. Principal of loans and bonds, without leases and interest. The filing
- 2026: $954.0K
- 2027: $986.0K
- 2028: $1.0M
- 2029: $185M
- 2030: $1.1M
- 2031 on: $6.6M
The ladder at each year end
| Year | 1 yr | 2 yrs | 3 yrs | 4 yrs | 5 yrs | Later |
|---|---|---|---|---|---|---|
| 2025 | $954.0K | $986.0K | $1.0M | $185M | $1.1M | $6.6M |
| FY2025 | $3.4M | $967.0K | $1.0M | $175M | $1.1M | $7.3M |
| FY2024 | $773.0K | $773.0K | $773.0K | $773.0K | $773.0K | $161M |
The ladder at each year end
When LFCR's debt fell due, as each annual report set it out, from FY2013 to FY2022, 10 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Leases
Dec 31, 2025Operating leases
$1.5M
Finance leases
$5.9M
The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing
Operating lease payments by year
Goodwill by segment
Dec 31, 2025Total goodwill
$14M
The company does not state its goodwill by segment, at December 31, 2025. The filing
Goodwill by year
Goodwill by year
LFCR's goodwill from FY2012 to FY2023, 12 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
From the statutory to the effective tax rate, FY2025
May 25, 2025Statutory rate
21.0%
Effective rate
-0.1%
The company paid -0.1% in tax on its profit, 21.1 points below the US federal rate (21.0%). Below, the reasons it gives.
Statutory rate
21.0%
Impairments
+1.9 pts
Tax credits
+1.4 pts
State and local taxes
+0.5 pts
Change in valuation allowance
-22.1 pts
Share-based compensation
-2.1 pts
Prior-year adjustments
-0.6 pts
Other
-0.3 pts
Effective rate
-0.1%
One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing
Effective tax rate by year
In a year of a loss or of very small profits the rate comes out negative or very large and says little. Those years are in grey.
Effective tax rate by year
The tax rate LFCR paid on its profit, from FY2011 to FY2022, 12 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Claims ahead of shareholders
What stands between the business and its shareholders besides the debt, and the financial assets on the other side, from the latest balance sheet.
$51M of other claims rank ahead of the shares, about 21% of the market value.
Ahead of the shares
- at Sep 30, 2026
- $51M
From the balance sheet of September 30, 2026. The retirement and environmental lines and the pension deficit come from the latest annual report when the quarter's filing does not state them, each with its own date. Market value at the price of November 20, 2026. A line is listed when it is at least 0.5% of the market value. A description of the balance sheet, not a valuation.
Earnings quality
How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.
Taxes: deferred and paid
The deferred part was -276.7% of the tax charge in the year to May 25, 2025. The rows show the last 3 years.
Cash taxes paid were 28.4% of the current tax charge in the year to May 25, 2025.
- Cash taxes paid against the current charge are lower than at nine in ten S&P 500 companies.
- Deferred share, year to May 25, 2025-$119.0K of $43.0K
- -276.7%
- Deferred share, year to May 26, 2024$156.0K of $183.0K
- 85.3%
- Deferred share, year to May 28, 2023$254.0K of $308.0K
- 82.5%
- $46.0K paid, $162.0K current
- 28.4%
When profit in the accounts runs ahead of taxable profit, the deferred part grows. It also moves for reasons unrelated to how earnings are booked: tax-law changes, the use of past losses, and the US rule since 2022 that spreads research costs over five years. Where the notes report it, the tax-rate bridge under Debt and obligations shows how the rate gets from the statutory one to the effective one.
The earnings per share split is not shown: it needs a profit before tax in both years, since a tax rate on a loss has no meaning as a source.
Receivables and inventory against sales are not shown: a figure it needs is missing from the company's structured filings.
The allowance for doubtful accounts is not shown: the company does not tag it in its structured filings.
A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.
The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.
The full analysis
What do Lifecore Biomedical's filings show?
These are Lifecore Biomedical's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much revenue did LFCR have in FY2025?
Lifecore Biomedical had revenue of $129M and net income of -$39M in fiscal FY2025, a net margin of -30.0%.
How much debt does LFCR have?
On May 25, 2025 Lifecore Biomedical had total assets of $239M, debt of $134M and shareholders' equity of $1.3M.
How much free cash flow does LFCR have?
In fiscal FY2025 Lifecore Biomedical had cash from operations of -$206.0K and spent $13M on capital expenditure, leaving -$14M of free cash flow.
Where are the figures from?
From Lifecore Biomedical, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.